CVS Health Corporation $CVS Stake Raised by Callahan Advisors LLC

Key Points

• Callahan Advisors LLC increased its stake in CVS Health by 136.8% during the second quarter, acquiring an additional 44,285 shares, bringing its total holdings to 76,650 shares valued at approximately $5.3 million.
• CVS Health reported a quarterly earnings per share of $1.81, exceeding analysts' expectations and indicating an 8.4% increase in revenue compared to the previous year.
• The company declared a quarterly dividend of $0.665 per share, with a payout ratio of 74.30%, and an annualized yield of 3.3%, reflecting its commitment to returning value to shareholders.

Callahan Advisors LLC grew its holdings in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 136.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 76,650 shares of the pharmacy operator's stock after buying an additional 44,285 shares during the period. Callahan Advisors LLC's holdings in CVS Health were worth $5,287,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Bell Investment Advisors Inc raised its holdings in shares of CVS Health by 119.8% during the first quarter. Bell Investment Advisors Inc now owns 455 shares of the pharmacy operator's stock valued at $31,000 after buying an additional 248 shares during the last quarter. Roxbury Financial LLC raised its holdings in shares of CVS Health by 78.3% during the second quarter. Roxbury Financial LLC now owns 460 shares of the pharmacy operator's stock valued at $32,000 after buying an additional 202 shares during the last quarter. ORG Partners LLC raised its holdings in shares of CVS Health by 418.9% during the second quarter. ORG Partners LLC now owns 467 shares of the pharmacy operator's stock valued at $32,000 after buying an additional 377 shares during the last quarter. Saudi Central Bank bought a new stake in shares of CVS Health during the first quarter valued at approximately $34,000. Finally, Livelsberger Financial Advisory bought a new stake in CVS Health during the second quarter worth approximately $35,000. Institutional investors own 80.66% of the company's stock.

CVS Health Trading Up 1.4%

NYSE CVS opened at $80.75 on Thursday. CVS Health Corporation has a twelve month low of $43.56 and a twelve month high of $81.93. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.62 and a current ratio of 0.80. The stock has a market cap of $102.42 billion, a price-to-earnings ratio of 22.56, a PEG ratio of 0.88 and a beta of 0.60. The firm's 50 day moving average price is $73.30 and its two-hundred day moving average price is $67.92.

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.46 by $0.35. CVS Health had a net margin of 1.17% and a return on equity of 10.51%. The firm had revenue of $98.92 billion for the quarter, compared to analysts' expectations of $94.87 billion. During the same period in the previous year, the company posted $1.83 EPS. The company's quarterly revenue was up 8.4% compared to the same quarter last year. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts anticipate that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Thursday, October 23rd will be issued a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 3.3%. The ex-dividend date is Thursday, October 23rd. CVS Health's payout ratio is currently 74.30%.

Insider Activity at CVS Health

In other news, Director Anne A. Finucane sold 7,500 shares of the business's stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total transaction of $532,650.00. Following the transaction, the director directly owned 22,156 shares in the company, valued at $1,573,519.12. The trade was a 25.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.22% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on CVS shares. Bernstein Bank dropped their target price on CVS Health from $78.00 to $72.00 and set a "market perform" rating on the stock in a report on Wednesday, July 16th. Robert W. Baird raised CVS Health from a "neutral" rating to an "outperform" rating and boosted their target price for the stock from $71.00 to $82.00 in a report on Thursday, August 14th. Truist Financial set a $92.00 target price on CVS Health in a report on Tuesday. Wall Street Zen raised CVS Health from a "hold" rating to a "buy" rating in a report on Sunday, September 21st. Finally, Baird R W upgraded shares of CVS Health from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 14th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $81.05.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.